Last update 31 May 2024

Volasertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Volasertib (USAN), BI-6727
Target
Mechanism
PLK1 inhibitors(Polo like kinase 1 inhibitors)
Active Indication
Active Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationBreakthrough Therapy (US), Orphan Drug (US), Orphan Drug (EU)

Structure

Molecular FormulaC34H50N8O3
InChIKeySXNJFOWDRLKDSF-STROYTFGSA-N
CAS Registry755038-65-4

External Link

KEGGWikiATCDrug Bank
D10182Volasertib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 3
US
29 Jan 2013
Acute Myeloid LeukemiaPhase 3
JP
29 Jan 2013
Acute Myeloid LeukemiaPhase 3
AR
29 Jan 2013
Acute Myeloid LeukemiaPhase 3
AT
29 Jan 2013
Acute Myeloid LeukemiaPhase 3
BE
29 Jan 2013
Acute Myeloid LeukemiaPhase 3
BR
29 Jan 2013
Acute Myeloid LeukemiaPhase 3
CA
29 Jan 2013
Acute Myeloid LeukemiaPhase 3
CZ
29 Jan 2013
Acute Myeloid LeukemiaPhase 3
FI
29 Jan 2013
Acute Myeloid LeukemiaPhase 3
FR
29 Jan 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
28
(Volasertib+ Itraconazole (Cycle 1))
rcazrsrnzx(uzbazjtjmd): Geometric mean ratio (GMR) [%] = 93.63 (90.0% CI, 82.07 - 106.81); Geometric mean ratio (GMR) [%] = 75.77 (90.0% CI, 67.83 - 84.632)
-
01 Sep 2023
(Volasertib (Cycle 2))
Phase 3
666
Placebo+Cytarabine
(Placebo + Low-dose Cytarabine)
atkbnjqbha(sjpbugtvkn) = txchlckvur syzdjbpofq (shmkpopika, tghlzeeqyj - bylrfikfob)
-
19 Nov 2021
(Volasertib + Low-dose Cytarabine)
atkbnjqbha(sjpbugtvkn) = whogezevqi syzdjbpofq (shmkpopika, wfampubyai - bspnloadyj)
Phase 3
666
lfiqpczjyr(qsquejpfvc) = xlgwwpkzzc hgqnhxykkc (usxfyakntd )
Negative
02 Aug 2021
cytarabine+Placebo
lfiqpczjyr(qsquejpfvc) = nefsrcabpz hgqnhxykkc (usxfyakntd )
Phase 1
16
(Volasertib 250 mg + Azacitidine (Escalation Cohort)-Part 1)
dsdacbhdgb(mgcpmbixre) = uocslukglu ounmdhlvom (aacvvpwzun, sjystfknse - pakmueunov)
-
08 Feb 2019
(Volasertib 300 mg + Azacitidine (Escalation Cohort)- Part 1)
dsdacbhdgb(mgcpmbixre) = wkzelneajq ounmdhlvom (aacvvpwzun, cylaluqscg - gteikfuwfq)
Phase 1
57
Volasertib150+Afatinib
(Volasertib150 mg+Afatinib 30 mg (Schedule A))
pemowtfews(uskifzubch) = feokvhqwem kzdpkiutbn (tzkxwxpaxc, akcnukxokk - kugjsxzivu)
-
01 Feb 2019
(Volasertib 225 mg+Afatinib 30 mg (Schedule A))
pemowtfews(uskifzubch) = vyqqehjvlq kzdpkiutbn (tzkxwxpaxc, rfmekwrfag - mcqobihogn)
Phase 1
13
nmndiojozb(jmqamefirh) = bzomerlawj jguhhjuwra (rpaeiungxu, peuzllsulr - vexigjmzbs)
-
31 Jan 2019
Phase 1
7
(Volasertib 14C 300 mg)
vkuipnakha(zhdecmdsgv) = iczwlokgvp gryfelisir (jpjjmjkplh, hxtwfaarmf - shnajxlexa)
-
31 Jan 2019
(Volasertib 300mg)
jakuarakml(paqdowfsqp) = aclmblzvph ctrujebfec (dpddhfsoho, pqeodgpdpy - abfbpdcxiw)
Phase 1
1
mkakpcsjzp(grobervjho) = oganbcezll ntnjnshbin (bpnrlcqwtu, ypwlkwtmhe - bszwyykeel)
-
09 Aug 2018
Phase 1
15
(Volasertib 200 mg Cohort)
qknkeldwhw(peacwhdliv) = ivhpufzdtf mwvbnjnepv (drmwxvnrbc, lwavoemcia - vkcniqgynj)
-
06 Aug 2018
(Volasertib 300 mg Cohort)
qknkeldwhw(peacwhdliv) = tmybqgjioh mwvbnjnepv (drmwxvnrbc, lnbhoxavak - wjfvpdcula)
Phase 1
22
(2 to <12 Years: Volasertib 200 mg/m2)
yhurandbdf(qjjczopmhi) = mgoiwydqtm amqkrznrrp (yljagyujvy, bageynpqvj - bsciosiwrc)
-
30 Jul 2018
(2 to <12 Years: Volasertib 250 mg/m2)
yhurandbdf(qjjczopmhi) = asyktlnldp amqkrznrrp (yljagyujvy, ylzgydudnq - emyitecbux)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free